KemPharm Inc. Daily Stock Analysis

Daily Stock Analysis, KMPH, KemPharm Inc, priceseries

KemPharm Inc. Daily Stock Analysis
Stock Information
Open
5.21
Close
5.46
High
5.59
Low
5.20
Previous Close
5.26
Daily Price Gain
0.20
YTD High
9.43
YTD High Date
Jan 3, 2022
YTD Low
5.20
YTD Low Date
Mar 7, 2022
YTD Price Change
-3.80
YTD Gain
-41.04%
52 Week High
15.70
52 Week High Date
Jun 14, 2021
52 Week Low
5.20
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-3.87
52 Week Gain
-41.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 27. 2017
68.80
Apr 10. 2017
73.31
10 Trading Days
6.55%
Link
LONG
Sep 13. 2017
52.80
Sep 29. 2017
59.49
12 Trading Days
12.68%
Link
LONG
Dec 27. 2017
63.20
Feb 5. 2018
92.55
26 Trading Days
46.44%
Link
LONG
May 10. 2018
84.80
May 30. 2018
99.01
13 Trading Days
16.76%
Link
LONG
Jan 4. 2019
34.72
Jan 31. 2019
42.59
18 Trading Days
22.65%
Link
LONG
May 16. 2019
21.28
May 31. 2019
25.67
10 Trading Days
20.64%
Link
LONG
Jan 2. 2020
6.48
Jan 14. 2020
7.99
8 Trading Days
23.34%
Link
LONG
Jul 24. 2020
4.88
Aug 27. 2020
11.56
24 Trading Days
136.94%
Link
LONG
Nov 17. 2020
10.24
Dec 3. 2020
14.32
11 Trading Days
39.84%
Link
LONG
Dec 17. 2020
15.66
Dec 21. 2020
17.59
2 Trading Days
12.32%
Link
LONG
Feb 2. 2021
6.50
Feb 23. 2021
9.22
14 Trading Days
41.87%
Link
LONG
Mar 15. 2021
11.93
Mar 16. 2021
12.87
1 Trading Days
7.84%
Link
LONG
May 27. 2021
10.05
Jun 18. 2021
13.12
15 Trading Days
30.51%
Link
Company Information
Stock Symbol
KMPH
Exchange
NasdaqGM
Company URL
http://www.kempharm.com
Company Phone
319-665-2575
CEO
Travis C. Mickle
Headquarters
Iowa
Business Address
2500 CROSSPARK ROAD, SUITE E126, CORALVILLE, IA 52241
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434647
About

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Its portfolio of product addresses pain, attention-deficit or hyperactivity disorder, and central nervous system. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Description

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading